Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | The management of cytopenias in MF

Prithviraj Bose • 10 Nov 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Luspatercept Pelabresib Ruxolitinib
COMFORT-I MANIFEST-2 PERSIST-2 SIMPLIFY-2

Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, gives a presentation on the management of cytopenias in myelofibrosis (MF) at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Prithviraj Bose

Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat 2:12
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat
Prithviraj Bose • 7 Dec 2025
Real-world treatment duration of ruxolitinib and transfusion use in patients with myelofibrosis 2:03
Real-world treatment duration of ruxolitinib and transfusion use in patients with myelofibrosis
Prithviraj Bose • 7 Dec 2025
Early analysis of ODYSSEY: momelotinib plus luspatercept in transfusion-dependent myelofibrosis 2:10
Early analysis of ODYSSEY: momelotinib plus luspatercept in transfusion-dependent myelofibrosis
Prithviraj Bose • 7 Dec 2025
Zilurgisertib with/without ruxolitinib in patients with anemia due to MF: Phase I/II final results 2:18
Zilurgisertib with/without ruxolitinib in patients with anemia due to MF: Phase I/II final results
Prithviraj Bose • 7 Dec 2025

Related Videos

Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US 2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat 2:12
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat
Prithviraj Bose • 7 Dec 2025
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs 2:40
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
Anand Patel • 25 Nov 2025
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes 4:47
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes
Daniel Wiseman • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals